GLPG1837 dose 2 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	2

299. 嚢胞性線維症

---

臨床試験数 : 1,696 /  薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02707562 (ClinicalTrials.gov)	February 2016	22/2/2016	Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)	A Phase IIa, Open-label Study of Multiple Doses of GLPG1837 in Subjects With Cystic Fibrosis and the G551D Mutation	Cystic Fibrosis	Drug: GLPG1837 dose 1;Drug: GLPG1837 dose 2;Drug: GLPG1837 dose 3	Galapagos NV	NULL	Completed	18 Years	N/A	Both	26	Phase 2	Australia;Czech Republic;Germany;Ireland;United Kingdom
2	NCT02690519 (ClinicalTrials.gov)	January 2016	16/2/2016	Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation)	A Phase IIa, Open-label Study of Two Doses of GLPG1837 in Subjects With Cystic Fibrosis and the S1251N Mutation	Cystic Fibrosis	Drug: GLPG1837 dose 1;Drug: GLPG1837 dose 2	Galapagos NV	NULL	Completed	18 Years	N/A	Both	7	Phase 2	Belgium;Netherlands